



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/49

August 05, 2026

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol – BIOCON

Subject: Press Release on financial results for the quarter ended June 30, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “**Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17%**” pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter ended June 30, 2026.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance officer
ICSI Membership Number: A16328

Enclosed: Press Release and Fact Sheet

PRESS RELEASE


Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17%

Bengaluru, Karnataka, India: August 5, 2026:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal first quarter ended June 30, 2026.

FINANCIAL PERFORMANCE

- Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business.
- Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.
 - Biosimilars revenue increased 16% YoY to Rs 2,855 crore.
 - Generics revenue increased 21% YoY Rs 760 crore.



Note: Revenue contribution as a % of Revenue from Operations

- Services revenue decreased 16% YoY to Rs 736 crore due to continued impact of challenges faced last year.
- Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%, supported by improved profitability in the Biopharma business, which helped offset continued challenges in the Services business.
- Interest cost at Rs 213 crore, down 23% YoY from Rs 277 crore, following the actions taken to strengthen Biocon's balance sheet.
- Net Profit before exceptionals was Rs 145 crore.

LEADERSHIP COMMENTS

"Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth."

– Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited

"Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™ and Aukelso™ (biosimilar Denosumab), Yesafili™ (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval

from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.”

– Shreehas Tambe, CEO & Managing Director, Biocon Limited

“As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth.

My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.”

– Siddharth Mittal, CEO & Managing Director, Syngene International Limited

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY27

In Rs Crore

Particulars	Q1FY27	Q1FY26	YoY (%)
INCOME			
Biosimilars	2,855	2,458	16%
Generics	760	630	21%
Biopharma (Biosimilars + Generics)	3,615	3,088	17%
Services	736	875	(16%)
Inter-segment	(15)	(21)	28%
Revenue from operations[#]	4,336	3,942	10%
Other income	55	80	(31%)
Total Income	4,391	4,022	9%
Net R&D Expenses	240	205	17%
EBITDA	902	846	7%
EBITDA Margins	21%	21%	
PBT (before Exceptional items)	141	114	24%
PBT (after Exceptional items[^])	128	97	32%
Net Profit (before Exceptional Items^{^^})	145	42	245%
Net Profit (Reported)	141	31	355%

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above:

[#]Revenue from operations includes licensing income

[^]Exceptional items during Q1FY27 and Q1FY26 amount to Rs (13) crore and Rs (17) crore, respectively

^{^^}Net of tax and minority interest, exceptional items during Q1FY27 and Q1FY26 amounted to Rs. (4) crore and Rs. (11) crore respectively, resulting in a Net Profit of Rs 141 crore and Rs 31 crore, respectively

BUSINESS PERFORMANCE - Biopharma

North America

- Growth in North America region was driven by the ramp-up of recently launched biosimilars, including Bosaya™ and Aukelso™ (biosimilar Denosumab) in the U.S., coupled with stable performance in the oncology portfolio.
- Commercialized Yesafili™ (aflibercept-jbvf) in the U.S., in August, as an interchangeable biosimilar Aflibercept.
- Secured Health Canada Notice of Compliance (NOC) for Yesintek® (biosimilar Ustekinumab) autoinjector pen.
- Commercialized generic Liraglutide in the U.S.

Europe

- Commercialized Evfraxy® (biosimilar Denosumab), for bone health, across multiple European markets.
- Commercialized Abevmy® (biosimilar Bevacizumab) from oncology portfolio in Czech Republic and Switzerland.

Emerging Markets

- Expanded market access through multiple product approvals and commercial partnerships across Emerging Market countries.
- Secured approval for Yesafili™ as Malaysia's first biosimilar Aflibercept.
- Maintained strong market leadership for biosimilar Bevacizumab franchise in Brazil.

BUSINESS PERFORMANCE - Services

- Signed MoU with BRIC-Translational Health Science and Technology Institute (THSTI) for early and late-phase clinical development, translational research, and bioanalytical sciences. The collaboration will enable the evaluation and execution of First-in-Human (FIH) and Phase I clinical programs, along with bioanalytical, biomarker and patient-based clinical research programs.
- Continued to strengthen Syn.AI, an AI-enabled scientific platform for accelerating drug discovery services, by developing giga scale virtual screening capabilities. This will enable screening and prioritizing larger libraries of molecules, accelerating the identification of promising drug candidates.

Board Updates

- Bobby Parikh has completed his term as an Independent Director of the Company with effect from the close of business hours of July 22, 2026.
- Nicholas Haggar shall complete his term as an Independent Director of the Company with effect from the conclusion of the ensuing 48th Annual General Meeting of the Company scheduled to be held on August 6, 2026.
- The Board places on record its appreciation for their valuable services and contributions during their tenure with the Company.

Awards and Recognitions

- Kiran Mazumdar-Shaw ranked No. 4 in 'Biopharma' category on The Global Medicine Maker Power List 2026.
- Kiran Mazumdar-Shaw recognized for 'Lifetime Contribution to UK-India Relations' at the 10th edition of India Global Forum's UK-India Week.
- Kiran Mazumdar-Shaw ranked No. 6 on Fortune India's 100 Most Powerful Women 2026 list.

- Biocon recognized as a trailblazing brand at the 8th ET NOW's Iconic Brands of India.

Sustainability / ESG

- Biocon's Bio-Pure Project recognized with the 'Sustainability Initiative of the Year' Award 2026 by International Health Partners at the Medicines for Europe Conference.
- Biocon recognized as 'Company of the Year' at the Sustainability & CSR Malaysia Awards 2026, marking its third consecutive win.

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: [@bioconlimited](https://twitter.com/bioconlimited) LinkedIn: [Biocon](https://www.linkedin.com/company/biocon)

About Syngene International Ltd.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit [Syngene ESG Report](#).

FOR MORE INFORMATION	
For Media Rumman Ahmed Head – External Communications, Biocon +91 98451 04173 rumman.ahmed@biocon.com	For Investors Prashant Nair Head – Investor Relations, Biocon +91 98200 95476 Prashant.nair@biocon.com

Earnings Call

The management of the Company will host an Earnings Call on **August 6, 2026 at 10:00 AM IST**, over a webcast, where the senior management will discuss the Company's performance and answer questions from participants. Details of the webcast are given below as well as on the Company website www.biocon.com under Investors >> Financial Calendar >> Earnings Call for the period ended June 30, 2026. Transcript of the conference call will be uploaded on the Company website in due course.

Zoom Webinar Details	
Date	August 6, 2026
Time	10:00 AM IST
Join Zoom Webinar	Click here to register to the earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

BIOCON GROUP

FACT SHEET

June - 2026

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 27	Q1 FY 26	Variance %
INCOME			
Biopharmaceuticals			
-Biosimilars	2,855	2,458	16%
-Generics	760	630	21%
Services*	736	875	-16%
Inter-segment revenue	(15)	(21)	28%
Revenue from operations #	4,336	3,942	10%
Other income	55	80	-31%
TOTAL REVENUE	4,391	4,022	9%
EXPENDITURE			
Material & Power costs	1,599	1,514	6%
Staff costs	868	783	11%
Research & Development expenses	240	205	17%
Other expenses	782	675	16%
Manufacturing, staff & other expenses	3,489	3,176	10%
EBITDA	902	846	7%
Interest & Finance charges	213	277	-23%
Depreciation & Amortisation	548	455	20%
PBT BEFORE EXCEPTIONAL ITEM	141	114	24%
Exceptional item, Net	(13)	(17)	
PBT	128	97	32%
Taxes	(6)	12	-150%
Taxes on exceptional item	(3)	(4)	
NET PROFIT BEFORE MINORITY INTEREST	137	89	54%
Minority interest	1	61	-98%
Minority interest on exceptional item	(5)	(3)	
NET PROFIT FOR THE PERIOD	141	31	355%
EPS Rs.	0.9	0.3	
NET PROFIT BEFORE EXCEPTIONAL ITEM	145	42	245%
Exceptional item, net of taxes	(4)	(11)	
NET PROFIT FOR THE PERIOD	141	31	355%
# Licensing Income	10	4	
* Earlier 'CRDMO'			

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q1 FY 27	Q4 FY 26	Variance %
INCOME			
Biopharmaceuticals			
-Biosimilars	2,855	2,756	4%
-Generics	760	776	-2%
Services*	736	1,037	-29%
Inter-segment revenue	(15)	(52)	71%
Revenue from operations #	4,336	4,517	-4%
Other income	55	53	4%
TOTAL REVENUE	4,391	4,569	-4%
EXPENDITURE			
Material & Power costs	1,599	1,514	6%
Staff costs	868	854	2%
Research & Development expenses	240	277	-13%
Other expenses	782	852	-8%
Manufacturing, staff & other expenses	3,489	3,496	0%
EBITDA	902	1,073	-16%
Interest & Finance charges	213	232	-8%
Depreciation & Amortisation	548	513	7%
PBT BEFORE EXCEPTIONAL ITEM	141	328	-57%
Exceptional item, Net	(13)	(80)	
PBT	128	248	-48%
Taxes	(6)	72	-108%
Taxes on exceptional item	(3)	(23)	
NET PROFIT BEFORE MINORITY INTEREST	137	199	-31%
Minority interest	1	77	-99%
Minority interest on exceptional item	(5)	(4)	
NET PROFIT FOR THE PERIOD	141	126	12%
EPS Rs.	0.9	0.8	
NET PROFIT BEFORE EXCEPTIONAL ITEM	145	179	-19%
Exceptional item, net of taxes	(4)	(53)	
NET PROFIT FOR THE PERIOD	141	126	12%
# Licensing Income	10	3	
* Earlier 'CRDMO'			

BIOCON LIMITED (CONSOLIDATED) BALANCE SHEET		
	(Rs Crores)	
Particulars	Jun 30, 2026	Mar 31, 2026
ASSETS		
Non-current assets		
(a) Property, plant and equipment	9,302	9,473
(b) Capital work-in-progress	4,885	4,613
(c) Right-of-use assets	561	578
(d) Goodwill	18,579	18,377
(e) Other intangible assets	7,917	8,058
(f) Intangible assets under development	2,392	2,374
(g) Financial assets		
Investments	1,620	1,089
Derivative assets	45	43
Other financial assets	420	596
(h) Income tax asset, net	413	429
(i) Deferred tax asset, net	609	556
(j) Other non-current assets	267	285
Non-current assets	47,010	46,471
Current assets		
(a) Inventories	6,733	6,086
(b) Financial assets		
Investments	479	690
Trade receivables	6,827	5,987
Cash and cash equivalents	1,518	2,417
Other bank balances	836	777
Derivative assets	32	22
Other financial assets	247	315
(c) Other current assets	1,014	886
Current assets	17,686	17,180
TOTAL - ASSETS	64,696	63,651
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	815	811
(b) Other equity	34,414	33,221
Equity attributable to owners of the Company	35,229	34,032
Non-controlling interests	2,317	2,590
Total Equity	37,546	36,622
Non-current liabilities		
(a) Financial liabilities		
Borrowings	10,600	10,746
Lease liabilities	521	537
Derivative liabilities	35	68
Other financial liabilities	560	555
(b) Other non-current liabilities	464	481
(c) Provisions	340	330
(d) Deferred tax liability, net	223	243
Non-current liabilities	12,743	12,960
Current liabilities		
(a) Financial liabilities		
Borrowings	4,353	4,078
Lease liabilities	77	72
Trade payables	7,281	6,772
Derivative liabilities	191	248
Other financial liabilities	693	967
(b) Other current liabilities	1,116	1,260
(c) Provisions	215	256
(d) Income tax liability, net	481	416
Current liabilities	14,407	14,069
TOTAL - EQUITY AND LIABILITIES	64,696	63,651